BioCentury
ARTICLE | Company News

Gilead buys Sarepta PRV, mum on plans

February 22, 2017 12:03 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) declined to comment on plans for the Priority Review voucher it acquired on Monday. The company paid $125 million to Sarepta Therapeutics Inc. (NASDAQ:SRPT), which gained the voucher last September when FDA approved Exondys 51 eteplirsen to treat Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping (see BioCentury Extra, Sept. 19, 2016).

Gilead's late stage pipeline includes Janus kinase-1 (JAK-1) inhibitor filgotinib (GS-6034), which is in Phase III development to treat Crohn's disease (CD), ulcerative colitis (UC) and rheumatoid arthritis (RA); and Phase III gastric cancer candidate GS-5745, a matrix metalloproteinase 9 (MMP9) mAb inhibitor. The company also has selonsertib (GS-4997), an apoptosis signal-regulating kinase 1 (ASK1; MAP3K5) inhibitor, in the Phase III STELLAR 3 and STELLAR 4 trials to treat non-alcoholic steatohepatitis (NASH). ...